GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

LXRX · Jun 30, 2025

LEXICON PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001628280-25-038340General Corporate

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

58.87% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

1685.16% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

0.58% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

99.89% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

12.94% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

54.55% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

11.09% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History10 statesHistory building

Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20240/7 normalizedLevel 3 Mar 31, 20250/8 normalizedLevel 3 Jun 30, 20250/7 normalizedLevel 3 Sep 30, 20250/8 normalizedLevel 3 Dec 31, 20250/9 normalizedLevel 3 Mar 31, 20266/8 normalizedLevel 3 Jun 30, 20266/8 normalizedLevel 3

Period transition

What moved in the state?

Cash Generation Increased

Previous: -3468.94%
Current: 58.87%
Delta: 3527.81%

Growth Increased

Previous: 15.46%
Current: 1685.16%
Delta: 1669.70%

Inventory Pressure Decreased

Previous: 15.93%
Current: 0.58%
Delta: -15.35%

Margin Increased

Previous: 97.62%
Current: 99.89%
Delta: 2.26%

Profitability Increased

Previous: -2034.79%
Current: 12.94%
Delta: 2047.73%

R And D Intensity Decreased

Previous: 1212.60%
Current: 54.55%
Delta: -1158.05%

Sbc Intensity Decreased

Previous: 241.13%
Current: 11.09%
Delta: -230.04%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · LXRX Fundamental State →Has State · LEXICON PHARMACEUTICALS, INC. →Transitioned To · LXRX Fundamental State →Transitioned To · LXRX CASH_GENERATION_INCREASED →Transitioned To · LXRX GROWTH_INCREASED →Transitioned To · LXRX INVENTORY_PRESSURE_DECREASED →Transitioned To · LXRX MARGIN_INCREASED →Transitioned To · LXRX PROFITABILITY_INCREASED →Transitioned To · LXRX R_AND_D_INTENSITY_DECREASED →Transitioned To · LXRX SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.